Pioneering ECP Immunomodulation for over 30 years
Therakos is a specialty brand of Mallinckrodt – a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies.
For over 30 years, we have played a pioneering role in advancing the science of immunotherapy delivered through ECP. We continue to invest in the highest standards of medical education, while seeking to refine our technologies, and remaining dedicated to furthering advances in ECP Immunomodulation.
Our THERAKOSTM CELLEXTM Photopheresis System is the only fully integrated and validated system for the delivery of ECP.1
We strive to provide innovative therapeutic platforms and comprehensive support services to help healthcare professionals deliver optimised ECP Immunomodulation to patients.
We are dedicated to helping improve patients’ lives. That’s why we offer a comprehensive range of support services to healthcare professionals to help them feel more confident in delivering ECP Immunomodulation to their patients.
Dedicated to the practice and technological advancement of ECP for over 30 years
In 1987, we pioneered ECP treatment with the launch of our unique and innovative THERAKOSTM UVAR XTSTM System, which gained FDA approval the following year. Since then, we have been the only providers of fully integrated and validated ECP systems.
Our current platform, the THERAKOSTM CELLEXTM Photopheresis System, first arrived in 2009. It has since been used to deliver over 1 million treatments and is used in over 300 treatment centres across 30 countries.2
Technological advancements from 1987 to today
The evolution of our integrated ECP
Beyond the THERAKOSTMCELLEXTM Photopheresis System, we offer a range of support services to help enable healthcare professionals deliver optimised ECP Immunomodulation to patients.
Education And Knowledge Sharing
Our education and knowledge sharing, delivered through the Therakos Institute, is a valuable tool to healthcare professionals. It provides high-quality professional education provided by leading clinicians, scientific advisors and nurse trainers.
Patient and Funding Access
We offer patient and funding access support through a number of different initiatives. This helps us to advance the knowledge and clinical practice of ECP Immunomodulation for future generations.
Scientific and Clinical Partnerships
Through ourscientific and clinical partnerships, we strive to maintain the highest possible standards – uniting with leading figures across the world to ensure we provide the strongest possible service.
Comprehensive Customer Support
A key part of our service is providingcomprehensive customer support. Our aim is to help front-line users feel confident in delivering ECP Immunomodulation treatment to patients.
ECP, extracorporeal photopheresis; FDA, Food and Drug Administration.
1.Knobler R, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2693-2716.2.Therakos (UK) Ltd. Data on File – ref-05174.